ArticleScientific reports2026
Sarcopenia and fall-related outcomes in Chinese adults aged 45 years or older: a longitudinal cohort study.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Sarcopenia, the progressive loss of muscle mass and function, is a significant health concern in middle-aged and older adults, potentially linked to adverse outcomes like falls and fractures. A cohort study was conducted utilizing participants aged ≥ 45 years from CHARLS. Sarcopenia was defined using established criteria. Primary outcomes were isolated falls, isolated hip fractures, and composite outcomes. Associations were assessed using multivariable Cox regression (adjusted for confounders), propensity score matching (PSM), and inverse probability weighting (IPW), reporting hazard ratios (HRs) and 95% confidence intervals (CIs).Conduct sensitivity analyses such as stratification to control for confounding. Among 6,939 participants (42.6% with sarcopenia), 10-year incident rates were 39.7% for isolated falls, 3.3% for isolated hip fractures, and 1.7% for composite outcomes. Sarcopenia was persistently associated with an increased risk of isolated falls across all analyses (adjusted HR = 1.20, 95% CI:1.10–1.31, p < 0.01; PSM HR = 1.19, p < 0.01; IPW HR = 1.26, p < 0.001). For isolated hip fractures, significant associations were found in adjusted (HR = 1.60, 95% CI:1.17–2.17, p = 0.003) and IPW analyses (HR = 1.78, p = 0.01), but not PSM (HR = 0.99, 95%CI:0.68–1.44, p = 0.958). No significant association was found between sarcopenia and composite outcomes.Sensitivity analysis confirmed the robustness of the results. Sarcopenia is a significant risk factor for falls in middle-aged and older Chinese adults. Its association with hip fractures requires further investigation due to inconsistent findings across analytical methods.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.